Table 1 Association of patient/tumor characteristics with CHEK2 H371Y mutation status
Characteristics | n | Carriers, n (%) | Non-carriers, n (%) | P-value |
|---|---|---|---|---|
Total | 2334 | 39 (1.7) | 2295 (98.3) | Â |
Age | Â | Â | Â | 0.036 |
  ≤50y | 1415 | 30 (76.9) | 1385 (60.3) |  |
  >50y | 919 | 9 (23.1) | 910 (39.7) |  |
ER | Â | Â | Â | 0.30 |
  Positive | 1365 | 26 (66.7) | 1339 (58.3) |  |
  Negative | 969 | 13 (33.3) | 956 (41.7) |  |
PgR | Â | Â | Â | 0.26 |
  Positive | 1108 | 22 (56.4) | 1086 (47.3) |  |
  Negative | 1226 | 17 (43.6) | 1209 (52.7) |  |
HER2 | Â | Â | Â | 0.038 |
  Positive | 714 | 6 (15.4) | 708 (30.8) |  |
  Negative | 1620 | 33 (84.6) | 1587 (69.2) |  |
TNBC | Â | Â | Â | 0.61 |
  Non-TNBC | 1837 | 32 (82.1) | 1805 (78.6) |  |
  TNBC | 497 | 7 (17.9) | 490 (21.4) |  |
Tumor size | Â | Â | Â | 0.70 |
  <2 cm | 786 | 12 (30.8) | 774(33.7) |  |
  ≥2 cm | 1548 | 27 (69.2) | 1521(66.3) |  |
Lymph node | Â | Â | Â | 1.00 |
  Positive | 1014 | 17 (43.6) | 997 (43.6) |  |
  Negative | 1314 | 22 (56.4) | 1292 (56.4) |  |
  Unknown | 6 |  | 6 |  |
Nuclear grade | Â | Â | Â | Â |
  1 | 199 | 6(17.6) | 193 (9.7) | 0.29 |
  2 | 1518 | 24(70.6) | 1494 (75.3) |  |
  3 | 302 | 4(11.8) | 298 (15.0) |  |
  Unknown | 315 | 5 | 310 |  |
Histology | Â | Â | Â | 0.45 |
  Ductal | 2064 | 33 (84.6) | 2031 (88.5) |  |
  Others | 270 | 6 (15.4) | 264 (11.5) |  |
Chemotherapy type | Â | Â | Â | 0.27 |
  A-based,without a T | 859 | 18 (46.2) | 841 (36.6) |  |
  A-T containing | 882 | 10 (25.6) | 872 (38.0) |  |
  T-based,without a A | 593 | 11(28.2) | 582(25.4) |  |
Trastuzumab use | Â | Â | Â | 0.42 |
  Yes | 108 | 3 (7.7) | 105(4.6) |  |
  No | 2226 | 36 (92.3) | 2190(95.4) |  |
Surgery type | Â | Â | Â | Â |
  BCS | 983 | 22 (56.4) | 961 (41.9) | 0.07 |
  Mastectomy | 1351 | 17 (43.6) | 1334 (58.1) |  |